Seqirus is a new subsidiary of CSL, resulting from the acquisition of Novartis’ influenza vaccines business. It will be the second largest influenza vaccines business in the US$4 billion global industry and will have manufacturing plants in the US, UK, Germany and Australia with a commercial presence in approximately 20 countries. Maidenhead has been chosen as the location for its Headquarters.
Modus is delighted to have been selected as Seqirus’ preferred partner for the fit out via a tender process administered by Cushman & Wakefield. This success is continuing evidence of Modus’ commitment to delivering quality fit out projects nationally throughout the UK, with attention to detail, professionalism and customer experience the team’s guiding principles.